ARTMS in the News

QUANTM Irradiation System™ Earns CE Mark Approval

First-in-class, advanced technology enables production of high-value radioisotopes on medical cyclotrons

VANCOUVER, August 8, 2018 — ARTMS Products today announced it received CE marking approval
for its first-in-class, advanced technology QUANTM Irradiation System TM for producing high-value
radioisotopes, such as Tc-99m and Ga-68, on medical cyclotrons. Cyclotron facilities are constantly
facing higher isotope costs and poor supply availability. Now, with CE marking, ARTMS’ QUANTM
Irradiation System™ will help ease these issues.

“CE marking is an important milestone for ARTMS,” remarked Dr. Kaley Wilson, CEO of ARTMS
Products. “There is a huge opportunity in providing a cost effective and secured supply of radioisotopes
to hospitals and research institutions. ARTMS provides a more economical, environmentally safe and
secured supply of important radioisotopes than reactor-based sources. Now, with CE marking approval,
ARTMS can be readily integrated in a standardized fashion into existing and emerging facilities which
ultimately leads to improved patient access and care across Europe.”

Giving Cyclotron Facilities More Control Over the Supply of Medical Isotopes

Unlike traditional reactor and generator production methods, which are growing increasingly more
expensive and cannot consistently supply user requirements, the ARTMS QUANTM Irradiation
System™ combines both local production control and a cost-effective, easy-to-use solid target system for
production of radioisotopes on medical cyclotrons. Medical radioisotopes are used in the field of nuclear
medicine on a daily basis for both medical diagnostic imaging and therapy, particularly in the fields of
oncology, cardiology and neurology.

The ARTMS QUANTM Irradiation System™ is currently available for most OEM cyclotron systems
and has been installed and is operating in a number of countries.

About ARTMS Products

Based in Vancouver, British Columbia, ARTMS Products Inc. is a leader in the development of novel
technologies and products which enable the production of the world’s most-used diagnostic imaging
isotope, technetium‐99m (Tc‐99m), using local, hospital-based medical cyclotrons. ARTMS holds the
exclusive global commercialization rights to award-winning and proprietary Canadian inventions which
address these challenges, and which offer the prospect of revolutionizing the nuclear medicine industry.
For more information on the QUANTM Irradiation System™ and ARTMS Products, please follow us on
Twitter @Quantm99 and LinkedIn and visit